Y C Mi
Overview
Explore the profile of Y C Mi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su M, Yan Z, Li Q, Zhang J, Yin Y, Hu B, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2025 Mar;
46(1):53-57.
PMID: 40059682
This study analyzed the clinical characteristics and early mortality risk factors in patients with hyperleukocytic acute leukemia (HAL) to provide a basis for predicting early prognosis. Data were retrospectively collected...
2.
Yan Z, Li Y, Zhang B, He J, Li J, Wei S, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2024 Jul;
45(4):387-390.
PMID: 38951068
The efficacy and safety of venetoclax combined with reduced dose HAD regimen in the treatment of newly diagnosed acute myeloid leukemia (AML) was investigated. From May 2022 to January 2023,...
3.
Hou J, Liu K, Hu Y, Wei S, Zhang G, Zhou C, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2023 Jan;
43(9):778-780.
PMID: 36709173
No abstract available.
4.
Li Y, Huang X, Lin Y, Chen X, Chen L, Liu E, et al.
Zhonghua Bing Li Xue Za Zhi
. 2022 Nov;
51(11):1135-1140.
PMID: 36323543
To investigate the mutational features of the immunoglobulin heavy chain variable region (IgHV) gene in patients with chronic lymphocytic leukemia (CLL) using immunophenotypic and molecular genetic methods. The laboratory results...
5.
Yang M, Li L, Wei H, Liu B, Liu K, Li D, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2022 Jun;
43(4):336-341.
PMID: 35680634
To retrospectively analyze the data of Chinese patients with newly diagnosed acute promyelocytic leukemia (APL) to preliminarily discuss the clinical and cytogenetic characteristics. From February 2004 to June 2020, patients...
6.
Li C, Wei S, Qiu S, Gong B, Gong X, Li Y, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2022 Jun;
43(4):287-292.
PMID: 35680626
To evaluate the efficacy and toxicity profiles of idarubicin, cytarabine, and cyclophosphamide (IAC) in relapse/refractory acute myeloid leukemia (AML) . This study was a prospective, randomized controlled clinical trial with...
7.
Zhang C, Qiu S, Gong B, Gong X, Li Y, Liu Y, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2022 Jun;
43(5):383-387.
PMID: 35680595
To compare the efficacy of two induction regimens, namely, idarubicin combined with cytarabine (IA) versus the combination of homoharringtonine, daunorubicin, and cytarabine (HAD) , in adult patients with newly diagnosed...
8.
Huang X, Lin Y, Liu E, Xing F, Wang Z, Chen X, et al.
Zhonghua Bing Li Xue Za Zhi
. 2022 Mar;
51(4):307-313.
PMID: 35359041
To analyze the genetic landscape of 52 fusion genes in patients with de novo acute lymphoblastic leukemia (ALL) and to investigate the characteristics of other laboratory results. The fusion gene...
9.
Hao Q, Wang Z, Fang Q, Gong X, Liu K, Li Y, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2022 Jan;
42(11):911-916.
PMID: 35045652
To investigate the effect of genetic polymorphisms of TPMT*2 rs1800462, TPMT*3B rs1800460, TPMT*3C rs1142345, and NUDT15 rs116855232 on the tolerance of 6-mercaptopurine (6-MP) therapy in adult acute lymphoblastic leukemia (ALL)...
10.
Yan Q, Lin Y, Huang X, Qian L, Ma J, Zhang H, et al.
Zhonghua Xue Ye Xue Za Zhi
. 2021 Aug;
42(6):480-486.
PMID: 34384154
To analyze the genetic landscape of multiple fusion genes in patients with de novo acute myeloid leukemia (AML) and investigate the characteristics of immunophenotypes and mutations. The results of multiple...